MedWatch

Novo Nordisk plugs hemorrhage with lucrative Biopharm unit restored to growth

The Danish pharmaceutical giant's golden business area has made it through recent years with more skin left on its nose than many had feared a few years back.

Photo: Novo Nordisk / PR

The most lucrative unit of Novo Nordisk's business, Biopharm, has stopped capital from hemorrhaging and is in fact now restored to to growth.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs